MGAT1-deficient cells and their use
MGAT1-deficient cell lines enable controlled glycosylation of viral antigens, addressing structural challenges and improving vaccine efficacy against SARS-CoV-2 variants by enhancing immune response.
JP2026517008APending Publication Date: 2026-05-27ROCK BIOMEDICAL INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ROCK BIOMEDICAL INC
- Filing Date
- 2024-05-16
- Publication Date
- 2026-05-27
AI Technical Summary
Technical Problem
Existing methods for producing viral antigens with modified glycosylation face challenges such as altered protein structure and reduced immunogenicity, limiting the development of broad-spectrum protective vaccines against pathogens like SARS-CoV-2.
Method used
The development of MGAT1-deficient cell lines through RNA-induced endonuclease and gRNA intervention to modify glycosylation pathways, enabling the production of glycoproteins with oligomannose glycan at N-glycosylation sites, which are then expressed and isolated to enhance immune response.
Benefits of technology
This approach allows for the production of glycoproteins with controlled glycosylation patterns, enhancing immune response and providing better protection against viral variants.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026517008000001_ABST
Abstract
A method for producing modified cells lacking mannosyl(alpha-1,3)-glycoprotein beta-1,2-N-acetylglucosamine transferase 1 ("MGAT1") activity is provided. The MGAT1 activity-deficient CHO cell line produced by this method is also provided. A method for producing glycoproteins is further disclosed.
Need to check novelty before this filing date? Find Prior Art